These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8795084)

  • 1. GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1.
    Gallwitz B; Witt M; Morys-Wortmann C; Fölsch UR; Schmidt WE
    Regul Pept; 1996 May; 63(1):17-22. PubMed ID: 8795084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells.
    Gallwitz B; Witt M; Fölsch UR; Creutzfeldt W; Schmidt WE
    J Mol Endocrinol; 1993 Jun; 10(3):259-68. PubMed ID: 8396943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor.
    Gelling RW; Wheeler MB; Xue J; Gyomorey S; Nian C; Pederson RA; McIntosh CH
    Endocrinology; 1997 Jun; 138(6):2640-3. PubMed ID: 9165060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma.
    Volz A; Göke R; Lankat-Buttgereit B; Fehmann HC; Bode HP; Göke B
    FEBS Lett; 1995 Oct; 373(1):23-9. PubMed ID: 7589426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide.
    Hinke SA; Manhart S; Speck M; Pederson RA; Demuth HU; McIntosh CH
    Life Sci; 2004 Aug; 75(15):1857-70. PubMed ID: 15302229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.
    Moens K; Heimberg H; Flamez D; Huypens P; Quartier E; Ling Z; Pipeleers D; Gremlich S; Thorens B; Schuit F
    Diabetes; 1996 Feb; 45(2):257-61. PubMed ID: 8549871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
    Holst JJ
    BioDrugs; 2002; 16(3):175-81. PubMed ID: 12102645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors.
    Moon MJ; Kim HY; Kim SG; Park J; Choi DS; Hwang JI; Seong JY
    Mol Cells; 2010 Aug; 30(2):149-54. PubMed ID: 20799012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity.
    Graziano MP; Hey PJ; Strader CD
    Recept Channels; 1996; 4(1):9-17. PubMed ID: 8723643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
    Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM
    Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
    Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure/activity characterization of glucagon-like peptide-1.
    Gallwitz B; Witt M; Paetzold G; Morys-Wortmann C; Zimmermann B; Eckart K; Fölsch UR; Schmidt WE
    Eur J Biochem; 1994 Nov; 225(3):1151-6. PubMed ID: 7957206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells.
    Watanabe Y; Kawai K; Ohashi S; Yokota C; Suzuki S; Yamashita K
    J Endocrinol; 1994 Jan; 140(1):45-52. PubMed ID: 8138751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower glucose-dependent insulinotropic polypeptide (GIP) response but similar glucagon-like peptide 1 (GLP-1), glycaemic, and insulinaemic response to ancient wheat compared to modern wheat depends on processing.
    Bakhøj S; Flint A; Holst JJ; Tetens I
    Eur J Clin Nutr; 2003 Oct; 57(10):1254-61. PubMed ID: 14506486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulation and degradation of GIP and GLP-1.
    Deacon CF
    Horm Metab Res; 2004; 36(11-12):761-5. PubMed ID: 15655705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
    Mentlein R; Gallwitz B; Schmidt WE
    Eur J Biochem; 1993 Jun; 214(3):829-35. PubMed ID: 8100523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
    Meier JJ; Nauck MA; Kranz D; Holst JJ; Deacon CF; Gaeckler D; Schmidt WE; Gallwitz B
    Diabetes; 2004 Mar; 53(3):654-62. PubMed ID: 14988249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors.
    Brubaker PL; Drucker DJ
    Recept Channels; 2002; 8(3-4):179-88. PubMed ID: 12529935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of GIP, GLP-1, insulin and gastrin on ghrelin release in the isolated rat stomach.
    Lippl F; Kircher F; Erdmann J; Allescher HD; Schusdziarra V
    Regul Pept; 2004 Jun; 119(1-2):93-8. PubMed ID: 15093702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
    Green BD; Gault VA; O'harte FP; Flatt PR
    Curr Pharm Des; 2004; 10(29):3651-62. PubMed ID: 15579061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.